Cargando…
Importance of luminal membrane mesothelin expression in intraductal papillary mucinous neoplasms
The present study demonstrated that luminal membrane mesothelin expression is a reliable prognostic factor in gastric cancer. Intraductal papillary mucinous neoplasms (IPMNs) often exhibit a spectrum of dysplasia, ranging between adenoma and carcinoma. Therefore, an immunohistochemical analysis of m...
Autores principales: | EINAMA, TAKAHIRO, KAMACHI, HIROFUMI, NISHIHARA, HIROSHI, HOMMA, SHIGENORI, KANNO, HIROMI, ISHIKAWA, MARIN, KAWAMATA, FUTOSHI, KONISHI, YUJI, SATO, MASANORI, TAHARA, MUNENORI, OKADA, KUNIAKI, MURAOKA, SHUNJI, KAMIYAMA, TOSHIYA, TAKETOMI, AKINOBU, MATSUNO, YOSHIHIRO, FURUKAWA, HIROYUKI, TODO, SATORU |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356290/ https://www.ncbi.nlm.nih.gov/pubmed/25789005 http://dx.doi.org/10.3892/ol.2015.2969 |
Ejemplares similares
-
Mesothelin-Specific Immune Responses and Targeted Immunotherapy for Mesothelin-Expressing Tumors
por: Einama, Takahiro, et al.
Publicado: (2017) -
Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer
por: Einama, T, et al.
Publicado: (2012) -
The anti-mesothelin monoclonal antibody amatuximab enhances the anti-tumor effect of gemcitabine against mesothelin-high expressing pancreatic cancer cells in a peritoneal metastasis mouse model
por: Mizukami, Tatsuzo, et al.
Publicado: (2018) -
Mesothelin blockage by Amatuximab suppresses cell invasiveness, enhances gemcitabine sensitivity and regulates cancer cell stemness in mesothelin-positive pancreatic cancer cells
por: Matsuzawa, Fumihiko, et al.
Publicado: (2021) -
Analysis of the risk factors for early death due to disease recurrence or progression within 1 year after hepatectomy in patients with hepatocellular carcinoma
por: Kamiyama, Toshiya, et al.
Publicado: (2012)